Debt-free Balance SheetNo reported debt meaningfully reduces solvency and interest-rate risk and preserves strategic optionality. For a cash-burning biotech, a debt-free structure lowers near-term bankruptcy risk, makes equity or partnership financing feasible, and supports continued R&D investment over months.

Very High Gross MarginsNear-100% gross margins indicate product economics that could scale favorably once commercialized. That structural margin advantage gives the company leverage to achieve profitability faster as revenue recovers, supporting long-term operating leverage if fixed costs are controlled.

Specialized Cell Therapy R&DA focused platform in engineered immune-cell therapies represents a high-barrier, IP-driven business model. Durable advantages include specialized know-how, regulatory moats, and partnership appeal to larger pharma, which can translate into licensing, collaborations, or milestone funding over time.

Bears Say

Shrinking, Volatile RevenueSteep, persistent revenue declines undermine scalability and indicate weak commercial traction or one-off revenues. Reduced top-line compresses operational leverage, makes R&D funding harder to justify internally, and raises the probability the firm will need dilutive financing absent a durable recovery.

Chronic Negative Operating Cash FlowConsistent negative operating cash flow forces reliance on external capital to sustain R&D and trials. That ongoing cash burn elevates financing and dilution risk, constrains strategic flexibility for partnerships or commercialization, and limits the firm's runway without new funding.

Large Net Losses & Negative ROEPersistent, sizable losses and negative ROE signal that shareholder capital is not generating returns and is being eroded. Over months this reduces equity cushions, increases pressure for dilutive raises or asset sales, and complicates long-term investor alignment absent a clear path to profitability.

4893 FAQ

What was Noile-Immune Biotech Inc.’s price range in the past 12 months?

Noile-Immune Biotech Inc. lowest stock price was ¥120.00 and its highest was ¥214.00 in the past 12 months.

What is Noile-Immune Biotech Inc.’s market cap?

Noile-Immune Biotech Inc.’s market cap is ¥7.40B.

When is Noile-Immune Biotech Inc.’s upcoming earnings report date?

Noile-Immune Biotech Inc.’s upcoming earnings report date is May 19, 2026 which is in 66 days.

How were Noile-Immune Biotech Inc.’s earnings last quarter?

Noile-Immune Biotech Inc. released its earnings results on Feb 13, 2026. The company reported -¥4.36 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.36.

Is Noile-Immune Biotech Inc. overvalued?

According to Wall Street analysts Noile-Immune Biotech Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Noile-Immune Biotech Inc. pay dividends?

Noile-Immune Biotech Inc. does not currently pay dividends.

What is Noile-Immune Biotech Inc.’s EPS estimate?

Noile-Immune Biotech Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Noile-Immune Biotech Inc. have?

Noile-Immune Biotech Inc. has 43,276,764 shares outstanding.

What happened to Noile-Immune Biotech Inc.’s price movement after its last earnings report?

Noile-Immune Biotech Inc. reported an EPS of -¥4.36 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.938%.

Which hedge fund is a major shareholder of Noile-Immune Biotech Inc.?

Currently, no hedge funds are holding shares in JP:4893

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Noile-Immune Biotech Inc.

Noile-Immune Biotech Inc. researches and develops CAR-T cells for cancer immunotherapies. The company was incorporated in 2015 and is headquartered in Minato, Japan.